Tata Chemicals Shares Surge Over 5% As Morgan Stanley Ups Rating And Target Price
Shares of Tata Chemicals Ltd. rallied 5.21% on Tuesday, buoyed by a bullish outlook from Morgan Stanley, which upgraded the stock to ‘Overweight' from ‘Underweight' and raised its target price by over 34% to Rs 1,127 from Rs 839.
The global brokerage cited multiple tailwinds for the company, including a recovery in earnings, operational turnaround in overseas units, and easing capital expenditure pressures.
“With an earnings trough now behind us (FY25), we think Tata Chemicals can benefit from higher volumes from expanded capacities in India, turnaround in UK operations, and stronger contribution from Rallis,” Morgan Stanley said in its note.
Morgan Stanley highlighted that Tata Chemicals' UK operations showed signs of a turnaround in the first quarter of FY26, while its India business is expected to benefit from full-scale capacity utilisation.
“Turnaround in UK performance and Kenya operations, full scale-up of India operations, and deriving cost efficiencies are key near-term triggers,” the brokerage noted.
The firm also pointed to a strong performance from Rallis India, Tata Chemicals' agri-input subsidiary, as the global agriculture cycle begins to normalise.
“Rallis delivered a strong beat in Q1FY26, and we expect its contribution to strengthen as the ag-cycle stabilises globally,” it added.
Morgan Stanley believes Tata Chemicals has moved past its peak capital expenditure phase, which should support margin expansion and improve return metrics.
The brokerage also observed that China's soda ash prices are near cycle troughs, which could provide price stability in the near term, especially as global capacity expansions are being delayed and older facilities are being rationalised.
Despite being down 11% year-to-date, Tata Chemicals has outperformed the Nifty over the past three months, reflecting improving earnings momentum, the note said.
-
High US Salaries, No Green Card Certainty: The Financial Calculation Facing Indian H-1B Families
The suspension of PERM processing at eight technology employers does not cancel existing H-1B visas. What it does is force a question many Indian families have been avoiding: is the US salary worth tying your career and family plans to one employer?
-
Unhedged Position: Can India See An Indonesia-Style Time Correction?
The Nifty is trading below levels it first clocked in 2024. Is there, then, as I have suggested in the headline, potential that the current time correction drags on painfully for the next three-five, even ten years?
-
Navigating Friction And Energy Realities: An Analysis Of Marco Rubio's October Visit To India
Occurring at a critical juncture marked by stalled trade negotiations and escalating geopolitical pressures over global energy supplies, the visit offers a profound window into modern US-India relations.
-
India Exports Capital. Why Not Export Trusteeship?
The big question, then, is whether India can build an institution that global borrowers, investors, banks, and lawyers can trust, even without an Indian connection.
-
France's Economy & Politics Are In Crisis | The Reason Why
Let's look at how the French economy and politics evolved under Nicolas Sarkozy, Franois Hollande and Emmanuel Macron.
-
You May Inherit The Business. You Must Earn Its Credibility.
Succession tests the founder's ability to share authority as much as it tests the next generation's readiness to assume it.
-
Signing Deals Is One Thing; Making Them Work Is Another | The Week In Whys
Sometimes, things don't turn out as planned. Indian companies have lost some bids to rivals, some projects won't produce until 2030.
-
FOMC Wall, PERM Suspension, Hospital Stocks | Talking Points This Week
A PERM suspension would directly affect green-card sponsorship rather than H-1B visas, so the near-term earnings impact could remain relatively limited. The key question is whether this marks a new phase in US scrutiny of Indian IT.
-
Everything, Everywhere, All At Once: Dalal Street's Week To Forget | Joining The Dots
Visa curbs, a Starlink spat and cancer drug caps: what connects this week's shocks for Indian markets
-
India Is Going Abroad For Critical Minerals. But It May Take Years To Pay Off | The Reason Why
Although India's steps are in the right direction, they remain modest compared with India's growing dependence.